# Trans Genic Inc.

http://www.transgenic.co.jp Technical Support: techstaff@transgenic.co.jp

### KC597

## Anti Human GRHPR Monoclonal Antibody

### Clone No. 1H1

For research use only

KC597 Code No. GRHPR Target Category Cancer 9380 Gene ID HGNC:4570 **Primary Source** PH2; GLXR; GLYD **Synonyms** Monoclonal Antibody Туре Partial peptide of Human GRHPR Immunogen (C-terminal region, 227-236aa) GANP® mouse Raised in [IHC] Rat kidney tissue P3U1 Myeloma 1H1 **Clone number** Purification ProteinG Serum-free medium Source Isotype lgG1, κ Human,Rat **Cross Reactivity** Unlabeled Label Concentration 0.25 mg/mL Contents(Volume) 50µg(200 µL/vial) Buffer PBS [containing 2% Block Ace as a stabilizer, 0.1% Proclin as a bacteriostat] Store at - 20°C long term, store at 4°C short term. Avoid Storage repeated freeze-thaw cycles. ELISA,IHC,WB Application WB IHC **ELISA** ICC

10-20 5.0-10 1.0 Not tested IP FCM IF Neutralization Not tested Not tested Not tested Not tested (µg/mL)

#### Reference

1. "Identification and expression of a cDNA for human hydroxypyruvate/glyoxylatereductase." Rumsby G. et al. Biochim. Biophys. Acta 1446:383-388(1999) [PubMed: 10524214] [Abstract]. Cited for: NUCLEOTIDE SEQUENCE [MRNA], SUBUNIT. Tissue: Liver. 2. "The gene encoding hydroxypyruvatereductase (GRHPR) is mutated in patients with primary hyperoxaluria type II." Cramer S.D. et

al. Hum. Mol. Genet. 8:2063-2069(1999) [PubMed: 10484776] [Abstract]. Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], INVOLVEMENT IN HP2. Tissue: Liver.

3. Liu B. et al. Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases. Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. Tissue: Aorta.

#### **UniPlot Summary**


//Function Enzyme with hydroxy-pyruvate reductase, glyoxylate reductase and D-glycerate dehydrogenase enzymatic activities. Reduces hydroxypyruvate to D-glycerate, glyoxylate to glycolate oxidizes D-glycerate to hydroxypyruvate.

//Catalytic activity Glycolate + NADP+ = glyoxylate + NADPH. D-glycerate + NAD(P)+ = hydroxypyruvate + NAD(P)H.

//Subunit structure Homodimer.

//Tissue specificity Ubiquitous. Most abundantly expressed in the liver.

//Involvement in disease Defects in GRHPR are the cause of hyperoxaluria primary type 2 (HP2) [MIM:260000]; also known as primary hyperoxaluria type II (PH2). HP2 is a disorder where the main clinical manifestation is calcium oxalate nephrolithiasis though chronic as well as terminal renal insufficiency has been described. It is characterized by an elevated urinary excretion of oxalate and Lglycerate



This product is generated from GANP® mice.